INT33892

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.23
First Reported 1986
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 2.96
Pain Relevance 1.84

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (CD177)
Anatomy Link Frequency
Th17 cells 1
BFA 1
CD177 (Homo sapiens)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 96 100.00 Very High Very High Very High
agonist 14 99.40 Very High Very High Very High
Immobilon 2 97.12 Very High Very High Very High
fortral 2 96.52 Very High Very High Very High
cytokine 37 95.24 Very High Very High Very High
narcan 4 84.44 Quite High
Kinase C 1 83.88 Quite High
abdominal pain 2 83.04 Quite High
Kappa opioid receptor 2 75.00 Quite High
methotrexate 15 74.56 Quite High
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 96 100.00 Very High Very High Very High
Intussusception 160 99.78 Very High Very High Very High
Gastroenteritis 16 94.96 High High
Autoimmune Disease 3 91.24 High High
Disease 34 89.12 High High
Fever 4 86.32 High High
Abdominal Pain 2 83.04 Quite High
Diarrhoea 4 82.40 Quite High
Vomiting 4 82.00 Quite High
Prolapse 2 56.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However, because the risk of intussusception associated with RRV-TV was highest during the week after vaccination, the incidence of intussusception following PRV was also evaluated for the 7 days after vaccination.
Positive_regulation (evaluated) of PRV associated with intussusception
1) Confidence 0.23 Published 2008 Journal Clinical Trials (London, England) Section Body Doc Link PMC2602609 Disease Relevance 0.71 Pain Relevance 0
Various formulations of PRV showed good efficacy (?
Positive_regulation (formulations) of PRV
2) Confidence 0.23 Published 2008 Journal Clinical Trials (London, England) Section Body Doc Link PMC2602609 Disease Relevance 1.12 Pain Relevance 0.08
BFA treatment enhanced down-regulation of the cell surface receptor induced by nonpeptide agonists, but not that by peptide agonists, and unmasked etorphine- and pentazocine-mediated receptor down-regulation.
Neg (not) Positive_regulation (induced) of cell surface receptor in BFA associated with fortral, agonist and immobilon
3) Confidence 0.19 Published 2006 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 16882876 Disease Relevance 0 Pain Relevance 0.84
and IL-6, both found to be increased in VERA patients, are known to promote the differentiation of Th17 cells, which in turn secrete IL-17A and IL-22 [28,29], two cytokines that were elevated in VERA patients and have an essential function in the pathogenesis of autoimmune diseases [29].
Positive_regulation (increased) of VERA in Th17 cells associated with autoimmune disease, rheumatoid arthritis and cytokine
4) Confidence 0.01 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2991033 Disease Relevance 1.13 Pain Relevance 0.79
Proenkephalin messenger RNA levels are regulated in response to cAMP analogues, activators of adenylate cyclase, nicotinic agonists and depolarization, suggesting that expression of the gene encoding proenkephalin is regulated by trans-synaptic events involving cell-surface-receptor activation.
Positive_regulation (activation) of cell-surface-receptor associated with agonist
5) Confidence 0.01 Published 1986 Journal Nature Section Abstract Doc Link 3020428 Disease Relevance 0 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox